A plain-language guide

nephropathic cystinosis

What's known, what's still uncertain, and what's actively debated, written plainly, and built only from published medical research.

Growing map · 30 sourced statements Every statement names its source Updated 2026-08-04
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. nephropathic cystinosis is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What's nephropathic cystinosis?

Nephropathic cystinosis is an autosomal recessive lysosomal storage disorder caused by variants in the CTNS gene, which encodes cystinosin, the lysosomal cystine transporter. Without working cystinosin, the amino acid cystine accumulates and crystallizes inside lysosomes throughout the body, causing progressive multi-organ damage. The infantile (nephropathic) form typically presents in the first year with renal Fanconi syndrome and, untreated, progresses to kidney failure; corneal cystine crystals and later endocrine, muscle, and other effects follow. The renal Fanconi syndrome of cystinosis is a proximal-tubule problem and is unrelated to Fanconi anemia, a separate bone-marrow disorder that shares only the name.

Also indexed asOMIM:219800, MONDO:0100151
Features mapped14
Treatments mapped3
Published sources13
Last reviewed2026-08-04

Signs and symptoms

Short stature

Short stature and impaired growth are common, driven by the renal losses and the body-wide effects of the disease.

Limited evidenceSource: PMID:38380220
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:40546328, OMIM:219800
Notesplain_language confirmed from PMID:40546328 via curation 2026-06-14. | regrounded primary OMIM:219800 -> PMID:38380220 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Growth delay

Slowed growth, sometimes called growth retardation, is one of the body-wide effects of cystinosis, alongside eye changes, an enlarged liver, an underactive thyroid, and muscle weakness.

Limited evidenceSource: PMID:14610675
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41783883, ORPHA:411629
Notesplain_language confirmed from PMID:41783883 via curation 2026-06-25 [claude-draft]. | regrounded primary ORPHA:411629 -> PMID:14610675 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Primary hypothyroidism

Cystine accumulation can affect the thyroid, leading to hypothyroidism, which is checked for and treated as part of routine follow-up.

Limited evidenceSource: PMID:40369127
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41783883, OMIM:219800
Notesplain_language confirmed from PMID:41783883 via curation 2026-06-14. | regrounded primary OMIM:219800 -> PMID:40369127 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Photophobia

As corneal crystals build up, many people develop photophobia (painful sensitivity to light) and, later, visual impairment.

Limited evidenceSource: PMID:29594088
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:40886257, ORPHA:411629
Notesplain_language confirmed from PMID:40886257 via curation 2026-06-14. | regrounded primary ORPHA:411629 -> PMID:29594088 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Corneal crystals

Cystine crystals deposit throughout the cornea from infancy. They are a characteristic finding of cystinosis and accumulate rapidly during childhood.

Limited evidenceSource: PMID:40369127
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41672367, ORPHA:411629
Notesplain_language confirmed from PMID:41672367 via curation 2026-06-14. | regrounded primary ORPHA:411629 -> PMID:40369127 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Visual impairment

In the eyes, cystinosis first shows up as cystine crystals in the cornea that cause no symptoms. Later it can cause photophobia and serious visual impairment.

Limited evidenceSource: PMID:40886257
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesOMIM:219800
Notesplain_language confirmed from PMID:40886257 via curation 2026-06-25 [claude-draft]. | regrounded primary OMIM:219800 -> PMID:40886257 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Renal Fanconi syndrome

Renal Fanconi syndrome is usually the first sign of nephropathic cystinosis. The kidney's proximal tubules leak salts, water, minerals, and nutrients, causing excessive urination, dehydration, electrolyte loss, and poor growth.

Limited evidenceSource: PMID:40369127
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:40912033, ORPHA:411629
Notesplain_language confirmed from PMID:40912033 via curation 2026-06-14. | regrounded primary ORPHA:411629 -> PMID:40369127 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Male infertility

Male infertility, often from azoospermia, is a recognized later complication in men with cystinosis, even when testosterone is normal.

Limited evidenceSource: PMID:40369127
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:40546328, OMIM:219800
Notesplain_language confirmed from PMID:40546328 via curation 2026-06-14. | regrounded primary OMIM:219800 -> PMID:40369127 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Stage 5 chronic kidney disease

Over time, untreated or under-treated disease progresses to chronic kidney disease and eventually kidney failure (end-stage renal disease), which may require dialysis or a transplant.

Limited evidenceSource: PMID:40912033
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesOMIM:219800
Notesplain_language confirmed from PMID:40912033 via curation 2026-06-14. | regrounded primary OMIM:219800 -> PMID:40912033 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Renal insufficiency

Nephropathic cystinosis usually appears in infancy with renal Fanconi syndrome. Without treatment, kidney function declines into chronic kidney disease and eventually end-stage kidney failure.

Limited evidenceSource: PMID:25345100
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:40912033, OMIM:219800
Notesplain_language confirmed from PMID:40912033 via curation 2026-06-25 [claude-draft]. | regrounded primary OMIM:219800 -> PMID:25345100 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Myopathy

Later in cystinosis, cystine deposits in muscle can cause progressive muscle weakness (myopathy), which may affect the hands, swallowing, and breathing muscles over time.

Limited evidenceSource: PMID:38380220
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41783883, OMIM:219800
Notesplain_language confirmed from PMID:41783883 via curation 2026-06-18 [carrie (curation)]. | regrounded primary OMIM:219800 -> PMID:38380220 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Hepatomegaly

As cystine accumulates in the liver over time, the liver can become enlarged (hepatomegaly). This is one of the systemic effects of cystinosis that can appear as the disease progresses beyond the kidneys and eyes.

Limited evidenceCurated reference: OMIM:219800
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41783883
Notesplain_language confirmed from PMID:41783883 via curation 2026-06-18 [carrie (curation)].
Last reviewed2026-06-18

Elevated intracellular cystine

In cystinosis the CTNS gene defect stops cystine from leaving the lysosome, so cystine builds up to high levels inside cells throughout the body. This intracellular accumulation crystallizes and progressively damages the kidneys, eyes, and other organs.

Limited evidenceSource: PMID:40912033
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42060142, OMIM:219800
Notesplain_language confirmed from PMID:42060142 via curation 2026-06-18 [carrie (curation)]. | regrounded primary OMIM:219800 -> PMID:40912033 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Elevated leukocyte cystine

The key test that confirms cystinosis is measuring the cystine level inside white blood cells (leukocytes), which is markedly elevated. This leukocyte cystine measurement is also used to monitor how well cysteamine treatment is working.

Limited evidenceSource: PMID:27102039
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:40912033, OMIM:219800
Notesplain_language confirmed from PMID:40912033 via curation 2026-06-18 [carrie (curation)]. | regrounded primary OMIM:219800 -> PMID:27102039 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

How it is diagnosed

Cystinosis, nephropathic

Diagnosed using: leukocyte cystine measurement.

Limited evidenceSource: PMID:40912033
The source text this rests on
“Diagnosis relies on clinical evaluation, corneal examination, leukocyte cystine quantification, and CTNS genetic testing.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:40912033 via curation 2026-06-25
Last reviewed2026-06-25

Cystinosis, nephropathic

Diagnosed using: CTNS gene testing.

Limited evidenceSource: PMID:40912033
The source text this rests on
“Diagnosis relies on clinical evaluation, corneal examination, leukocyte cystine quantification, and CTNS genetic testing.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:40912033 via curation 2026-06-25
Last reviewed2026-06-25

Cystinosis, nephropathic

Diagnosed using: slit-lamp examination.

Limited evidenceSource: PMID:41321547
The source text this rests on
“On slit-lamp examination, characteristic crystalline deposits were observed in the corneal stroma.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:41321547 via curation 2026-06-25
Last reviewed2026-06-25

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

cysteamine

Starting cysteamine early and taking it consistently is central to managing cystinosis. It helps delay kidney failure and reduce complications outside the kidney. Cysteamine must be taken lifelong.

Used to help with: Cystinosis, nephropathic.

Limited evidenceSource: PMID:40912033
The source text this rests on
“Cysteamine therapy, reduces intracellular cystine levels and delays disease progression, significantly improving patient outcomes.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41005824
Notesconfirmed from PMID:40912033 via curation 2026-06-14
Last reviewed2026-06-14

topical cysteamine

Cysteamine eye drops (topical cysteamine) are the only treatment that reduces the buildup of cystine crystals in the cornea. The drops work only while they are used consistently.

Used to help with: Cystinosis, nephropathic.

Limited evidenceSource: PMID:41321547
The source text this rests on
“…treated with topical cysteamine ophthalmic solution 0.44%, resulting in subjective improvement in photophobia and stabilization of corneal…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:40943162
Notesconfirmed from PMID:41321547 via curation 2026-06-14
Last reviewed2026-06-14

kidney transplantation

When the kidneys fail, a kidney transplant restores kidney function. The transplanted kidney does not develop the cystinosis kidney disease, but cystine still accumulates in other organs, so cysteamine and multidisciplinary care continue.

Used to help with: Cystinosis, nephropathic.

Limited evidenceSource: PMID:40912033
The source text this rests on
“Kidney transplantation remains a therapeutic option for end-stage renal…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:40912033 via curation 2026-06-14
Last reviewed2026-06-14

What changes how it shows up

Carrying the genetic change is not the whole story. The factors below are described in the research mapped here as changing whether, or how strongly, the condition appears. They modulate how the genotype is expressed; they do not, on their own, cause or cure it.

CTNS

Nephropathic cystinosis is caused by mutations in the CTNS gene, which carries the instructions for cystinosin, the protein that moves cystine out of the lysosome. When cystinosin does not work, cystine builds up inside the lysosome and damages organs throughout the body over time.

Described as modulating: Cystinosis, nephropathic.

Limited evidenceSource: PMID:40912033
The source text this rests on
“Cystinosis is a autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene, which encodes cystinosin, a cystine transporter. The defective function of cystinosin leads to cystine accumulation in the lysosome, resulting in progressive multi-organ damage.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:40912033 via curation 2026-06-25
Last reviewed2026-06-25

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.
No longer supportedLater, stronger evidence or guidance overturned this.

Where this comes from

This guide is built from 13 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

OMIM:219800 · Orphanet/HPO annotations for Cystinosis, nephropathic
ORPHA:411629 · Orphanet/HPO annotations for Infantile nephropathic cystinosis
PMID:14610675 · Early oral cysteamine therapy for nephropathic cystinosis.
PMID:25345100 · Cystinosis: clinical presentation, pathogenesis and treatment.
PMID:27102039 · Cystinosis: a review.
PMID:29594088 · Nephropathic Cystinosis: Symptoms, Treatment, and Perspectives of a Systemic Disease.
PMID:38380220 · The Clinical Manifestations and Disease Burden of Cystinosis in Saudi Arabia: A Single-Tertiary Center Experience.
PMID:40369127 · Long-term outcomes in nephropathic cystinosis: a review.
PMID:40886257 · Cystadrops® Eye Drops for the Management of Ocular Cystinosis in Patients Aged 6 Months to < 2 Years.
PMID:40912033 · Therapeutic strategies in cystinosis: A focus on cysteamine and beyond.
PMID:40943162 · From Molecular Understanding and Pathophysiology to Disease Management; A Practical Approach and Guidance to the Managem
PMID:41005824 · Phenotypic variability in cystinosis: Lessons from an atypical case.
PMID:41321547 · Shimmering Clarity: A Rare Case Report of Ocular Cystinosis.

Take it further

Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.